Kythera Biopharmaceuticals

About Kythera Biopharmaceuticals

Kythera Biopharmaceuticals, Inc. operated as a clinical-stage biopharmaceutical firm with a strategic focus on the aesthetic medicine market. The company was incorporated in Delaware in June 2004, initially as Dermion, Inc., and began operations in August 2005. It later changed its name to AESTHERx, Inc. before becoming Kythera Biopharmaceuticals, Inc. in July 2006. One of the co-founders, Jay Birnbaum, PhD, also served as the initial Chief Medical Officer. The company's core objective was to apply rigorous biotechnological and scientific practices to develop first-in-class prescription products for the rapidly expanding aesthetics sector, which is driven by consumer preference for non-surgical options.

Kythera's business centered on the discovery, development, and commercialization of prescription-based aesthetic treatments. The company's flagship product candidate was ATX-101, later branded as KYBELLA®, an injectable drug for reducing submental fat, commonly known as a "double chin". KYBELLA® is a formulation of deoxycholic acid, a naturally occurring molecule that aids in the breakdown and absorption of dietary fat. When injected into the fat under the chin, it works by destroying fat cells. The business model relied on gaining regulatory approval and then marketing this drug to physicians, such as dermatologists and plastic surgeons, who perform aesthetic procedures. A significant milestone was achieved on April 29, 2015, when the U.S. Food and Drug Administration (FDA) approved KYBELLA®, making it the first and only non-surgical injectable treatment for this condition.

Following its successful development and FDA approval of KYBELLA®, Kythera Biopharmaceuticals positioned itself as a significant entity in the facial aesthetics market. This culminated in a major strategic move on October 1, 2015, when Allergan plc (now a part of AbbVie) acquired Kythera in a transaction valued at approximately $2.1 billion. The acquisition integrated KYBELLA® into Allergan's extensive portfolio of aesthetic products, which included BOTOX® Cosmetic and JUVÉDERM®. The deal also included Kythera's development pipeline, such as setipiprant, a potential treatment for male pattern hair loss. This acquisition allowed Allergan to enhance its market-leading position and provide a broader range of aesthetic treatments to its global customer base.